@article{494a07fc61de4baeb361df30fc4cdc44,
title = "Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial",
author = "Rigby, {M. R.} and DiMeglio, {L. A.} and Rendell, {M. S.} and Felner, {E. I.} and Dostou, {J. M.} and Gitelman, {S. E.} and Patel, {C. M.} and Griffin, {K. J.} and E. Tsalikian and Gottlieb, {P. A.} and Greenbaum, {C. J.} and Sherry, {N. A.} and Moore, {W. V.} and R. Monzavi and Willi, {S. M.} and Philip Raskin and A. Moran and Russell, {W. E.} and A. Pinckney and L. Keyes-Elstein and M. Howell and S. Aggarwal and N. Lim and D. Phippard and Nepom, {G. T.} and J. McNamara and Ehlers, {M. R.}",
year = "2015",
month = feb,
day = "1",
doi = "10.1089/dia.2015.1510",
language = "English (US)",
volume = "17",
pages = "S81--S82",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
}